Anthony Barron speaks to ecancer at the WIN 2019 Symposium in Paris about the benefits of personalised treatments to patients, healthcare systems and society.
He explains the main benefits of this type of targeted treatment which include decreased hospitalisation costs, increased overall survival and reduced side effects.
Barron also mentions strategic and organisational barriers that still remain, including screening strategies and access to diagnostic technologies.
He also gives examples of some countries that have successfully implemented genomic strategies and national cancer plans. However, funding still remains to be the biggest hurdle in implementing an effective and accessible care strategy.